EUVIMEDEUVIMED entdecken
Crossref

Novel ester tethered dihydroartemisinin‐3‐(oxime/thiosemicarbazide)isatin hybrids as potential anti‐breast cancer agents: Synthesis, in vitro cytotoxicity and structure–activity relationship

Shaohuan Liu, Shu Wang, Dan Xu, Bowen Pan, Linzhi Chen, Shijia Zhao, Zhi Xu iD, Wei Zhou

Drug Development Research · 2023

DOI: 10.1002/ddr.22078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Shaohuan Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China. Hauptthemen laut MEDLINE: Isatin, Antineoplastic Agents, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of ester tethered dihydroartemisinin‐3‐(oxime/thiosemicarbazide)isatin hybrids 7a–p were designed, synthesized, and assessed for their antiproliferative activity against MCF‐7, MDA‐MB‐231, MCF‐7/ADR, and MDA‐MB‐231/ADR breast cancer cell lines. Among them, hybrids 7a,f (IC 50 : 1.33–3.84 µM) showed potent activity against triple‐negative (MDA‐MB‐231 and MDA‐MB‐231/ADR) breast cancer cell lines, and hybrid 7f (IC 50 : 3.90 and 10.18 µM) also demonstrated promising activity against estrogen receptor‐positive breast cancer cells (MCF‐7 and MCF‐7/ADR), and the activity was superior to these of artemisinin, dihydroartemisinin, and ADR, revealing their potential to fight against both drug‐sensitive and drug‐resistant breast cancers. The enriched structure–activity relationships may facilitate further design of more active candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsatinAntineoplastic AgentsBreast NeoplasmsHumansFemaleStructure-Activity RelationshipCell ProliferationMolecular StructureDrug Screening Assays, AntitumorCell Line, TumorArtemisininsSemicarbazides

Stichwörter der Autor:innen

breast cancerdihydroartemisininisatinstructure-activity relationshipthiosemicarbazide

Substanzen

IsatinAntineoplastic AgentsartenimolArtemisininsthiosemicarbazideSemicarbazides

Autor:innen und Institutionen

  • West China School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China.
  • School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
  • School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou, People's Republic of China.

ORCID-Profile: Zhi Xu

Zitieren

APA

Liu, S., Wang, S., Xu, D., Pan, B., Chen, L., Zhao, S., Xu, Z., & Zhou, W. (2023). Novel ester tethered dihydroartemisinin‐3‐(oxime/thiosemicarbazide)isatin hybrids as potential anti‐breast cancer agents: Synthesis, in vitro cytotoxicity and structure–activity relationship. Drug Development Research. https://doi.org/10.1002/ddr.22078

Vancouver

Liu S, Wang S, Xu D, Pan B, Chen L, Zhao S, et al. Novel ester tethered dihydroartemisinin‐3‐(oxime/thiosemicarbazide)isatin hybrids as potential anti‐breast cancer agents: Synthesis, in vitro cytotoxicity and structure–activity relationship. Drug Development Research. 2023. doi:10.1002/ddr.22078

BibTeX
@article{Liu2023,
  author = {Liu, Shaohuan and Wang, Shu and Xu, Dan and Pan, Bowen and Chen, Linzhi and Zhao, Shijia and Xu, Zhi and Zhou, Wei},
  title = {Novel ester tethered dihydroartemisinin‐3‐(oxime/thiosemicarbazide)isatin hybrids as potential anti‐breast cancer agents: Synthesis, in vitro cytotoxicity and structure–activity relationship},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22078}
}
Kostenlos starten →